PMCB PharmaCyte Biotech
- 1.860
- +0.100+5.68%
- 1.860
- 0.0000.00%
PharmaCyte Biotech News
PharmaCyte Biotech | 10-Q: Q1 2025 Earnings Report
PharmaCyte Biotech | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
PharmaCyte Biotech | 10-K: FY2024 Annual Report
PharmaCyte Biotech | NT 10-K: Others
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director WEINSTEIN ROBERT
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director WALKER WAYNE REMELL
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director Abecassis Michael M
PharmaCyte Biotech | SC 13D: Statement of acquisition of beneficial ownership by individuals-PharmaCyte Biotech, Inc.(83.4%)
PharmaCyte Biotech | 3: Initial statement of beneficial ownership of securities-10% Owner PharmaCyte Biotech, Inc.
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | ARS: Annual Report to Security Holders
PharmaCyte Biotech | DEF 14A: Definitive information statements
PharmaCyte Biotech | 10-Q: Q3 2024 Earnings Report
PharmaCyte Biotech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ayrton Capital LLC(9.9%),Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B(9.9%), etc.
PharmaCyte Biotech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(9.99%),Daniel B. Asher(9.99%), etc.
PharmaCyte Biotech | 10-Q: Q2 2024 Earnings Report
PharmaCyte Biotech | 3: Initial statement of beneficial ownership of securities-10% Owner PharmaCyte Biotech, Inc.
PharmaCyte Biotech | 8-K: Current report
Analysis
Price Target
No Data
No Data